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Background: Cardiovascular disease is the leading cause of death worldwide. Higher oxidative stress may
contribute to the pathogenesis of coronary artery disease (CAD). The purpose of this study was to investigate the
effect of L-carnitine (LC, 1000 mg/d) on the markers of oxidative stress and antioxidant enzymes activities in CAD
patients.
Methods: We enrolled 47 CAD patients in the study. The CAD patients were identified by cardiac catheterization as
having at least 50% stenosis of one major coronary artery. The subjects were randomly assigned to the placebo
(n = 24) and LC (n = 23) groups. The intervention was administered for 12 weeks. The levels of serum LC, plasma
malondialdehyde (MDA), and erythrocyte antioxidant enzymes activities [catalase (CAT), superoxide dismutase
(SOD), glutathione peroxidase (GPx)] were measured before and after intervention.
Results: Thirty-nine subjects completed the study (placebo, n = 19; LC, n = 20). After 12 weeks of LC supplementation,
the level of MDA was significantly reduced (2.0 ± 0.3 to 1.8 ± 0.3 μmol/L, P = 0.02) and the level of LC (33.6 ± 13.6 to
40.0 ± 12.0 μmol/L, P = 0.04) and antioxidant enzymes activities [CAT (12.7 ± 5.5 to 13.1 ± 5.8 U/mg of protein,
P = 0.02), SOD (14.8 ± 2.9 to 20.7 ± 5.8 U/mg of protein, P < 0.01), and GPx (20.3 ± 3.4 to 23.0 ± 3.1 U/mg of protein,
P = 0.01)] were significantly increased. The level of LC was significantly positively correlated with the antioxidant
enzymes activities (CAT, β = 0.87, P = 0.02; SOD, β = 0.72, P < 0.01).
Conclusion: LC supplementation at a dose of 1000 mg/d was associated with a significant reduction in oxidative
stress and an increase in antioxidant enzymes activities in CAD patients. CAD patients might benefit from using LC
supplements to increase their anti-oxidation capacity.
Trial registration: Clinical Trials.gov Identifier: NCT01819701.
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Cardiovascular disease is the leading cause of death
worldwide [1] and the second most common cause of
death in Taiwan. Research has demonstrated that higher
levels of oxidative stress play an important role in the
development of coronary artery disease (CAD) [2].* Correspondence: apt810@csmu.edu.tw
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unless otherwise stated.Consequently, administering antioxidants to CAD pa-
tients might improve their outcomes and prevent the
recurrence of CAD [3].
L-carnitine (LC) is a non-protein amino acid (β-
hydroxy-γ-trimethyl-amino-butyric acid), that is syn-
thesized from the essential amino acids lysine and
methionine [4]. LC facilitates β-oxidation of long-chain
fatty acids, participates in metabolism of branched chain
amino acids, and stabilizes cellular membranes [4,5].
Many in vitro and animal studies have reported that LC
is a free radical scavenger, which protects antioxidant. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Cao et al. [10] administered LC supplement (2000 mg/d)
to healthy volunteers and observed that LC significantly
increased the levels of antioxidant enzymes activities,
suggesting that LC might be useful for treating chronic
illnesses. Additionally, some clinical trials have attempted
to treat ischemic heart disease and other clinical condi-
tions of myocardial ischemia patients with higher doses
(≥2000 mg/d) of LC supplementation, and the results
show that LC has a protective effect on cardiac metab-
olism and function after intervention [11-13]. How-
ever, little information has been published about the
effect of LC on antioxidant status in CAD patients. It
would be worthwhile to know whether LC should be a
dietary supplement for CAD patients. Therefore, the
purpose of this study was to investigate the effect of
LC supplements (1000 mg/d) on the markers of oxida-




This study was designed as a single blind, randomized,
parallel, placebo-controlled trial. CAD patients were re-
cruited from the cardiology clinic of Taichung Veterans
General Hospital, which is a teaching hospital in central
Taiwan. CAD was identified by cardiac catheterization as
having at least 50% stenosis of one major coronary artery
or receiving percutaneous transluminal coronary angio-
plasty (PTCA). The patients with diabetes, liver, or renal
diseases were excluded to minimize the influence of
other cardiovascular risk factors. The patients under
medications therapy, such as acenocoumarol, thyroid
hormone, and warfarin, and those currently receiving
vitamin supplements were also excluded. Informed con-
sent was obtained from each subject. This study was ap-
proved by the Institutional Review Board of Taichung
Veterans General Hospital, Taiwan.
With a sample size calculation, we expected that the
change in the levels of antioxidant enzymes activities
would be 5.0 ± 7.0 U/mg of protein after LC supplemen-
tation; therefore, to achieve a desired power of 0.8 with
α value of 0.05, the minimum sample size was calculated
to be 18 subjects in each intervention group. We en-
rolled 47 CAD patients in this study and used a random
numbers table to randomly assign the subjects to the
placebo (n = 24) or to the LC [1000 mg/day, n = 23]
groups. The LC and placebo (starch) capsules were com-
mercially available preparations (New Health Taiwan
Co., Ltd.). The intervention was administered for
12 weeks. The subjects were instructed to take two cap-
sules daily (LC supplements 1000 mg/d, 500 mg/b.i.d).
To monitor compliance, the researchers reminded sub-
jects to check the capsules bag every 4 weeks to confirmthat the bag was empty, and we measured the level of
serum LC before and after intervention. The age, blood
pressures, and smoking, drinking, and exercise habits of
the subjects were recorded. The body weight, height,
and waist circumferences were measured, and the body
mass index (kg/m2) was calculated.
Blood collection and biochemical measurements
Fasting venous blood samples (15 mL) were obtained to
estimate the hematological and vitamin status. Blood
specimens were collected in Vacutainer tubes (Becton
Dickinson, Rutherford, NJ, USA) that contained EDTA
as an anticoagulant or that contained no anticoagulant
as required. Serum and plasma were prepared after cen-
trifugation (3,000 rpm, 4°C, 15 minutes) and were then
stored at −80°C until analysis. Hematological entities
(serum creatinine, total cholesterol, triglyceride, low
density lipoprotein-cholesterol, and high density
lipoprotein-cholesterol) were measured by an automated
biochemical analyzer (Hitachi-7180E, Tokyo, Japan). In
the present study, we used MDA assay as an indicator of
oxidative stress marker. MDA is generated in vivo via
peroxidation of polyunsaturated fatty acids and studies
show MDA can predict progression of CAD and carotid
atherosclerosis at 3 years [14,15]. Plasma malondialde-
hyde (MDA) was determined using the TBARs (thiobar-
bituric acid reactive substances) method, as described by
Botsoglou [16]. The serum level of LC was measured by
enzyme-linked immunosorbent assay (ELISA) using
commercially available kits (Cusabio, Wuhan, China) ac-
cording to the instructions made available from the
suppliers.
The red blood cells (RBCs) samples were washed with
normal saline after removing the plasma. Then, the
RBCs were diluted with 25× sodium phosphate buffer
for superoxide dismutase (SOD) and glutathione perox-
idase (GPx) measurements, and with 250× sodium phos-
phate buffer for catalase (CAT) measurement. The
antioxidant enzymes activities (CAT, SOD, and GPx)
were determined in the fresh samples. The methods for
measuring these activities have been described previ-
ously [17-19]. The protein content of the plasma and
RBCs was determined based on the biuret reaction of
the BCA kit (Thermo, Rockford, IL, USA). The values of
the antioxidant enzymes activities were expressed as
unit/mg of protein. All of the analyses were performed
in duplicate.
Statistical analyses
The data were analyzed using SigmaPlot software (version
12.0, Systat, San Jose, CA, USA). The normal distribu-
tion of variables was tested by the Kolmogorov-Smirnov
test. Differences in subjects’ demographic data and
hematological measurement data between the placebo
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Mann–Whitney rank sum test. The paired t-test or
Wilcoxon signed rank test was used to analyze the data
within each group before (baseline) and after interven-
tion (week 12). For categorical response variables, dif-
ferences between the two groups were assessed by the
Chi-square test or Fisher’s exact test. To examine the
relationships between the levels of LC and antioxidant
enzymes activities after supplementation, simple linear
regressions were used. Results were considered statisti-
cally significant at P < 0.05. Values presented in the text
are means ± standard deviations (SD).
Results
Study participant characteristics
The sampling and trial profiles are summarized in Figure 1
along with the number of subjects who completed the
study in each group. Table 1 shows the demographic data
and health characteristics of the subjects. There were
no significant differences between the two groups with
respect to age, blood pressure, anthropometric measure-
ments, hematological entities (serum creatinine and lipid
profiles), and the frequency of smoking, drinking, or
exercise at baseline.
Effects of LC supplementation on the levels of LC,
oxidative stress, and antioxidant enzymes activities
The levels of LC, oxidative stress, and antioxidant en-
zymes activities are shown in Figure 2. The subjects in
the LC group had significantly lower level of MDA (1.8 ±
0.3 versus 2.0 ± 0.4 μmol/L, P = 0.01), higher levels of LC
(40.0 ± 12.0 versus 35.2 ± 12.0 μmol/L, P = 0.02), and higherAssessed for
(n = 47, M/
Analysed
(n = 19, M/F = 19/0)
- Lost to follow-up
(n = 5, M/F = 5/0)
Placebo group





Figure 1 Flow diagram. F, female; LC, L-carnitine; M, male.activities of CAT (13.1 ± 5.8 versus 10.6 ± 2.9 U/mg of pro-
tein, P < 0.01), SOD (20.7 ± 4.2 versus 13.1 ± 2.9 U/mg of
protein, P < 0.01), and GPx (23.0 ± 3.1 versus 19.1 ± 2.3
U/mg of protein, P < 0.01) than those in the placebo
group at week 12. After LC supplementation, the level
of MDA was significantly reduced (2.0 ± 0.3 to 1.8 ±
0.3 μmol/L, P = 0.02) and levels of LC (33.6 ± 13.6 to
40.0 ± 12.0 μmol/L, P = 0.04) and antioxidant enzymes
activities (CAT, 12.7 ± 5.5 to 13.1 ± 5.8 U/ mg of pro-
tein, P = 0.02; SOD, 14.8 ± 2.9 to 20.7 ± 4.2 U/ mg of
protein, P < 0.01; and GPx, 20.3 ± 3.4 to 23.0 ± 3.1 U/mg of
protein, P = 0.01) were significantly increased from the
baseline.
The changed levels of oxidative stress and anti-
oxidant enzymes activities after supplementation are
shown in Table 2. The changed level of MDA (−0.2 ±
0.5 versus 0.1 ± 0.5 μmol/L, P = 0.03) was significantly
lower and the antioxidant enzymes activities (CAT, 2.0 ±
6.9 versus −0.9 ± 3.4 U/mg of protein, P = 0.02; SOD,
5.9 ± 4.9 versus −1.9 ± 5.7 U/mg of protein, P < 0.01; GPx,
2.7 ± 4.4 versus −1.4 ± 3.5 U/mg of protein, P < 0.01) were
significantly higher in the LC group than in the placebo
group.
Correlations between LC and antioxidant enzymes
activities after supplementation
The correlations between the levels of L-carnitine, oxidative
stress, and antioxidant enzymes activities after supplemen-
tation are shown in Table 3. After 12 weeks of supplemen-
tation, the level of LC was significantly correlated with the
antioxidant enzymes activities (CAT, β = 0.87, P = 0.02;
SOD, β = 0.72, P < 0.01). eligibility
F = 46/1)
Analysed 
(n = 20, M/F = 20/0)
- Lost to follow-up
(n=3, M/F = 2/1)
LC group




Declined to participate 
(n = 2, M/F = 2/0)
Table 1 Characteristics of subjects1
Placebo LC P
(n = 19) (n = 20) values2
Gender (male) 19 20 -
Age (y) 72.7 ± 10.1 (74.0) 71.9 ± 10.6 (72.0) 0.80
Systolic blood pressure (mmHg) 127.3 ± 6.0 (128.0) 128.4 ± 10.4 (130.0) 0.68
Diastolic blood pressure (mmHg) 74.5 ± 4.4 (74.0) 72.3 ± 4.7 (71.0) 0.22
Waist circumference (cm) 97.7 ± 11.4 (96.0) 91.4 ± 8.4 (91.5) 0.08
Waist hip ratio 0.9 ± 0.1 (0.9) 0.9 ± 0.1 (0.9) 0.09
Body mass index (kg/m2) 26.0 ± 2.4 (25.6) 24.8 ± 2.6 (24.6) 0.16
Creatinine (μmol/L) 106.1 ± 44.2 (97.2) 114.9 ± 26.5 (106.1) 0.33
Total cholesterol (mmol/L) 5.0 ± 1.2 (4.6) 4.9 ± 0.7 (4.9) 0.76
Triglyceride (mmol/L) 1.7 ± 0.7 (1.6) 1.4 ± 0.7 (1.1) 0.13
Low density lipoprotein-cholesterol (mmol/L) 3.0 ± 1.3 (3.0) 3.0 ± 0.7 (3.1) 0.97
High density lipoprotein-cholesterol (mmol/L) 1.2 ± 0.2 (1.2) 1.4 ± 0.4 (1.3) 0.10
Current smoker3, n (%) 3 (15.8%) 4 (20.0%) 1.00
Drink alcohol4, n (%) 3 (15.8%) 3 (15.0%) 1.00
Exercise5, n (%) 17 (89.5%) 20 (100%) 0.23
1mean ± SD (median).
2values are significantly different between the placebo and LC groups.
3current smoker: individual currently smoking one or more cigarettes per day.
4drink alcohol: individual drinking one or more drinks per day regularly.
5exercise: individual exercising at least 3 times every week.
LC, L-carnitine.
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To the best of our knowledge, this is the first clinical
study to examine the antioxidant activity in CAD pa-
tients after oral LC supplementation (1000 mg/d). In this
clinical trial, we have demonstrated that LC adminis-
tered at a dose of 1000 mg/d for 12 weeks significantly
reduced the oxidative stress and increased the antioxi-
dant enzymes activities in patients with CAD. After
12 weeks of LC supplementation at a dose of 1000 mg/d
can reduce the level of MDA by 7% and increase the ac-
tivities of CAT by 16%, SOD by 47%, and GPx by 12%.
Decreased RBCs antioxidative enzymes may accelerate
the development of atherosclerosis [20]. Increased RBCs
antioxidant enzymes activities can provide a protection
against oxidative damage to the endothelial cells [21]. In
the present study, there was a significant positive correl-
ation between the levels of LC and antioxidant enzymes
activities after supplementation. LC was found to be an
effective antioxidant agent in cardiovascular disease models
and prevent endothelial dysfunction through its antioxidant
property [8,21,22]. As a result, it seems clear that LC has a
protective effect against CAD, which could be ascribed
to its antioxidant capacity.
Gülçin et al. [8] have reported that LC might be a good
antioxidant. LC has an effect on free radicals (such as 1, 1-
diphenyl-2-picryl-hydrazyl radical, superoxide anion rad-
ical, hydrogen peroxide) scavenging. LC might interfere
with the reactive oxygen species formation and chelate themetal ferrous ions [8]. In the LC molecule, the carbonyl
group can stabilize the free radicals formed on α-carbon
with conjugation, and it protects plasma components
against the toxic action of reactive oxygen species and re-
active nitrogen species [8,9]. In addition, LC is also an es-
sential cofactor of carnitine palmitoyltransferase 1 (CPT1),
which allows fatty acid transport into mitochondria and
the incorporation of long chain fatty acids into the β-
oxidation cycle to obtain acetyl-CoA [23-25], and these
substances enter the tricarboxylic acid (TCA) cycle to
synthesize adenosine triphosphate (ATP). At this step of
ATP synthesis, a large amount of oxygen is consumed,
and the oxygen is reduced to water at the end of the TCA
cycle. Then, oxygen concentration decreases and reactive
oxygen species formation is also reduced [8,26]. We sug-
gest that LC could be acting as a buffer for excessive acetyl
groups in mitochondria, decreasing mitochondrial super-
oxide production during hypoxia or substrate excess, espe-
cially in the ischemic tissues.
During recent decades, much evidence has been ac-
quired that support a clear association between oxidative
stress and atherosclerotic plaque evolution [2,3,27-30].
Oxidative stress might play a crucial role in cardiac and
vascular abnormalities in different types of cardiovascu-
lar diseases, and antioxidant therapy might prove benefi-
cial in combating these problems [3,27]. Administering
LC at a higher dose (≥2000 mg) has shown a cardio-





















































































Figure 2 Levels of L-carnitine, oxidative stress, and antioxidant enzymes activities after supplementation. Data are means ± SD. □ week 0,
■ week 12. *Values were significantly different after intervention within the group. a, bValues with different superscripts were significantly different
between the two groups. CAT, catalase; GPx, glutathione peroxidase; LC, L-carnitine; MDA, malondialdehyde; SOD, superoxide dismutase.
Table 2 Changed levels of L-carnitine, oxidative stress
marker and antioxidant enzymes activities after
supplementation1
Placebo LC P values2
(n = 19) (n = 20)
LC (μmol/L) −1.2 ± 20.0 (0.8) 7.6 ± 15.2 (7.2) 0.04
MDA (μmol/L) 0.1 ± 0.5 (0.0) −0.2 ± 0.5 (−0.1) 0.03
CAT (U/mg protein) −0.9 ± 3.4 (−1.0) 2.0 ± 6.9 (1.8) 0.02
SOD (U/mg protein) −1.9 ± 5.7 (−1.2) 5.9 ± 4.9 (6.8) < 0.01
GPx (U/mg protein) −1.4 ± 3.5 (−1.3) 2.7 ± 4.4 (2.4) < 0.01
1mean ± SD (median).
2values are significantly different between the placebo and LC groups.
CAT, catalase; GPx, glutathione peroxidase; LC, L-carnitine; MDA, malondialdehyde;
SOD, superoxide dismutase.
Table 3 Correlations between the levels of L-carnitine,
oxidative stress, and antioxidant enzymes activities after
supplementation
LC(μmol/L)
β 1 P values
MDA (μmol/L) −0.00 1.00
CAT (U/mg protein) 0.87 0.02
SOD (U/mg protein) 0.72 < 0.01
GPx (U/mg protein) 0.08 0.72
1regression coefficient.
CAT, Catalase activity; GPx, glutathione peroxidase; LC, L-carnitine; MDA,
Malondialdehyde; SOD, superoxide dismutase.
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Taiwan recommends a daily dietary intake of no more
than 2000 mg of LC. As a result, we tested a dose of
1000 mg/d in CAD patients and expected that the dose
of LC (1000 mg/d) could be a dietary supplement for
daily use. Based on the results of this study, we suggest
that LC might be a useful dietary supplement for CAD
to protect against excessive oxidative stress.
Regarding the safety of LC supplementation, Singh
and Aslam [12] indicated that there are some side ef-
fects, such as mild nausea and vomiting after LC sup-
plement at a dose of 2000 mg/d, but in three divided
doses, supplementation might not cause any side ef-
fects. In the present study, we administered LC to CAD
patients at a dose of 1000 mg/d in two divided doses
(500 mg/b.i.d), and there were no clinically significant
changes in the subjects’ vital signs, serum chemical
values, or hematological values (such as blood urea ni-
trogen, creatinine, glutamic oxaloacetic transaminase,
or glutamic pyruvate transaminase); additionally there
were no serious adverse events, no complaints of myal-
gia or muscle weakness, no withdrawals due to adverse
events, and no cardiovascular event or death report dur-
ing and the end of the study. Therefore, we suggest that
a dose of 1000 mg/d is safe for CAD patients.
Recent work has suggested that dietary LC might
accelerate atherosclerosis via gut microbiota metabolites,
complicating the role of LC supplementation in health
[32]. We considered that the need for LC supplementa-
tion in CAD patients might be dependent on the status
of LC in the body. Thus, LC is considered a “condition-
ally essential nutrient. Animals and human studies have
shown that the content of LC was low in acute myocar-
dial infarction and chronic heart failure [33,34]. A recent
invited commentary in Mayo Clinic Proceedings clarifies
that there is no good reason to suspect that, within the
dose range used clinically, LC would promote athero-
sclerosis or otherwise compromise cardiovascular health.
To the contrary, there is ample reason to conclude that
carnitine is protective for vascular health [35]. As a re-
sult, it should be recommended that CAD patients with
lower levels of LC and higher oxidative stress take
LC supplements to increase their LC status and anti-
oxidation capacity.
There are some limitations of the present study that
should be mentioned. First, the number of participants
was small, although we did recruit more subjects than
expected. Second, this study was designed using daily
LC supplements for 3 months only. Larger and longer
intervention studies are needed to understand and estab-
lish the beneficial effects of a high dose of LC in patients
with CAD. Further study is also needed to measure more
mechanistic parameters and more direct indicators of
oxidative damage, such as nitrotyrosine, myeloperoxidase(MPO), or oxidized low density lipoprotein (ox LDL)
levels to understand the antioxidative mechanism of LC
in CAD patients.
Conclusions
In conclusion, we have demonstrated that LC supple-
mentation at a dose of 1000 mg/d significantly reduced
oxidative stress and increased antioxidant enzymes activ-
ities in CAD patients. CAD patients might benefit from
using LC supplements to increase their anti-oxidation
capacity.
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